본문으로 건너뛰기
← 뒤로

Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.

1/5 보강
Cancer management and research 📖 저널 OA 100% 2022: 5/5 OA 2023: 1/1 OA 2024: 6/6 OA 2025: 66/66 OA 2026: 53/53 OA 2022~2026 2025 Vol.17() p. 1859-1869
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
700 patients die on a regular basis in 2023 in America.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
However, because of several limitations existed in these clinical trials and alarmed long-term nephrotoxicity of PSMA-targeted therapy, we should be more prudent to this therapy. In this review, we evaluates the evolving clinical and preclinical landscape of PSMA-targeted therapy, as well as the potential biomarkers for evaluating the therapeutic response.

Wang J, Yuan H, Xu J, Yang C

📝 환자 설명용 한 줄

Prostate cancer (PCa) is the most common tumor for men in the genital system.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Wang J, Yuan H, et al. (2025). Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.. Cancer management and research, 17, 1859-1869. https://doi.org/10.2147/CMAR.S538367
MLA Wang J, et al.. "Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.." Cancer management and research, vol. 17, 2025, pp. 1859-1869.
PMID 40917757 ↗

Abstract

Prostate cancer (PCa) is the most common tumor for men in the genital system. Despite several new therapies approved in the past decades, 34,700 patients die on a regular basis in 2023 in America. Recently radioisotopic therapies have shown the delightful results in the PCa treatment, which made FDA approved lutetium-177 for adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer (mCRPC). Many other clinical trials are also in progress in various settings. Both monotherapy and combination studies are underway. However, because of several limitations existed in these clinical trials and alarmed long-term nephrotoxicity of PSMA-targeted therapy, we should be more prudent to this therapy. In this review, we evaluates the evolving clinical and preclinical landscape of PSMA-targeted therapy, as well as the potential biomarkers for evaluating the therapeutic response.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기